AUSTRALIAN REGIONAL HEALTH GROUP LIMITED

A.B.N. 44 067 435 714

EXCEPTIONAL DRUG FUNDING REQUEST FORM

Guidelines for Completion:

Exceptional Drug Funding (EDF) will only be considered for drugs that are not listed on the PBS and have an individual dose cost > EDF will not be automatically accepted and the decision to fund and to what level is at each individual fund's discretion. Funding will not be considered unless all aspects of this form are completed, are legible and request is signed by requesting medical practitioner.

General Information					
Member Name					D.O.B.
Health Fund					
Membership Number					
Requesting Medical Practitioner – Name and Contact D	etails				
	Phone:		Fax:		email:
Treating Hospital					
Contact Person – Name and Contact Details					
	Phone:		Fax:		email:
Date of Request					
Clinical Condition Information					
Principal Diagnosis	Grade/Stage of Disease				
Date of Diagnosis					
Comorbidities					
Previous Treatment given and reasons for not continuin	Ig				
Provision of baseline assessment (eg C antigen, PSA re	esult, mass size	e on CT scan etc)			
Quality of Life measure score – ECOG Performance Sta	atus Oo	$\bigcirc_1 \bigcirc_2$	<u> </u>	05	refer to attach for clarification of ECOG

Specific Medication Information

Drug Name – Trade and Generic Name				
Is Drug TGA Approved	⊖Yes ⊖No			
Are independent literature reviews available that document clinical trials the		equested use rovide either copies of document or referenci	Yes No	
Drug Company Manufacturer				
Is cost sharing process available through manufacturer	⊖ Yes ⊖ No	If yes, has this been accessed	⊖ Yes ⊖ No	
Details of cost sharing arrangement				
Is the hospital prepared to participate in a cost share arrangement	⊖Yes ⊖No			
Dosage	Proposed Number of doses per course			
Proposed Number of courses				
Will this treatment be longterm/ ongoing	◯ Yes ◯ No	If yes for how long?		
Frequency of dose				
Mode of administration				
Patient Status	O Inpatient Stay	◯ Same Day Stay		
Drug Charge/dose	Drug Charge/course			
Total Cost Requested				
Planned date of commencement	Planned date of comple	etion		
Treatment Outcome Information - select most appropriate res	ponse			
Is the treatment outcome expected to result in remission	⊖ Yes ⊖ No			
Is the treatment outcome expected to decrease progression of disease	⊖ Yes ⊖ No			
Is the treatment expected to be of a supportive nature and increase qualit	y of life with some improv	ement in life expectancy	◯ Yes ◯ No	
Is the treatment outcome expected to be of a supportive nature and increa quality of life with no expectation of improvement in life expectancy	ase		◯ Yes ◯ No	
Is the expected treatment outcome unknown	◯ Yes ◯ No			
Define evaluation process to monitor outcomes				

Requesting Medical Practitioner

ECOG PERFORMANCE STATUS

These scales and criteria are used by doctors and researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. They are included here for health care professionals to access.

ECOG PERFORMANCE STATUS*

Grade	ECOG
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5	Dead

* As published in Am. J. Clin. Oncol.:

Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.

The ECOG Performance Status is in the public domain therefore available for public use. To duplicate the scale, please cite the reference above and credit the Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.